LEAD-462

N/A

Report date: 2023/08/02 17:09:58

Base Information

Drug NameLEAD-462
Drug Alias NameLEAD-462
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsTumor necrosis factor receptor agonists
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLiver Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLeadartis SL
China Registration ClassN/A

Develop Information

Active CompaniesLeadartis SL
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLiver Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A